Mesoblast (NASDAQ:MESO) Cut to Hold at Jefferies Financial Group

Mesoblast (NASDAQ:MESO - Get Free Report) was downgraded by Jefferies Financial Group from a "buy" rating to a "hold" rating in a report released on Friday, Marketbeat reports.

Separately, Cantor Fitzgerald raised shares of Mesoblast to a "strong-buy" rating in a report on Monday, March 31st. One analyst has rated the stock with a sell rating, one has given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $18.00.

Mesoblast Trading Up 8.7%

MESO opened at $12.34 on Friday. The company has a fifty day simple moving average of $11.23 and a 200 day simple moving average of $13.62. The company has a debt-to-equity ratio of 0.22, a quick ratio of 0.63 and a current ratio of 0.96. Mesoblast has a 12 month low of $5.78 and a 12 month high of $22.00.

Institutional Investors Weigh In On Mesoblast

Several large investors have recently modified their holdings of the business. Bank of America Corp DE raised its stake in Mesoblast by 1,503.3% during the 4th quarter. Bank of America Corp DE now owns 290,728 shares of the company's stock worth $5,756,000 after buying an additional 272,595 shares during the period. Goldman Sachs Group Inc. bought a new position in Mesoblast in the 1st quarter worth $3,209,000. Summit X LLC raised its position in Mesoblast by 36.0% in the 1st quarter. Summit X LLC now owns 198,163 shares of the company's stock worth $2,473,000 after purchasing an additional 52,508 shares during the period. Oaktree Capital Management LP bought a new position in shares of Mesoblast during the fourth quarter valued at approximately $3,556,000. Finally, GAMMA Investing LLC raised its holdings in shares of Mesoblast by 1,174.2% in the first quarter. GAMMA Investing LLC now owns 85,513 shares of the company's stock worth $1,067,000 after buying an additional 78,802 shares during the last quarter. 1.43% of the stock is currently owned by institutional investors.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.